The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatoid Arthritis Prevention, Remission & Treatment De-Escalation

Rheumatoid Arthritis Prevention, Remission & Treatment De-Escalation

January 17, 2019 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Lightspring / shutterstock.com

Lightspring / shutterstock.com

CHICAGO—With an ever-strengthening foundation beneath the pathophysiology and prediction of rheumatoid arthritis (RA), the field may soon focus more intently on prevention, an expert said at the 2018 ACR/ARHP Annual Meeting. The session also covered the latest in remission targets and therapy de-escalation.

You Might Also Like
  • Destructive Arthritis: From Prevention to Progression to Remission
  • Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
Explore This Issue
January 2019
Also By This Author
  • Resarch Into IgG4-Related Diseases Expands Knowledge Base, Leads to Effective Treatments

RA Prevention

Kevin Deane, MD, PhD, associate professor of medicine and principal investigator on the Strategy for the Prevention of RA (StopRA) trial (funded by the National Institutes of Health [NIH]), wanted to spread “enthusiasm that within the next few years, rheumatology will be taking new ‘Intent to Prevent’ approaches to our diseases,” he said, using a phrase introduced by Marvin Fritzler, MD, PhD, of the University of Calgary, Canada.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Growing confidence in understanding the pathophysiology of RA and, in turn, predicting who will develop disease undergirds this shift, he said. Increasing elevations of anti-citrullinated protein antibodies (ACPAs) and cytokines are seen as clinical RA approaches, driven by an understanding of a shared epitope and such risk factors as female sex, smoking, diet, obesity and what we breathe, even though the mechanisms remain murky. A key, underexplored issue is the timing of the influence of these factors, Dr. Deane said.

Multiple studies have shown systemic autoimmunity in the absence of arthritis, making the case that RA-related autoimmunity starts outside the joints, with mounting evidence pointing to the mucosa.1,2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Knowing when and where RA starts can ultimately lead to effective interventions,” Dr. Deane said.

Prospective studies of ACPA-positive patients with and without rheumatoid factor have shown positive predictive values of 30–60% for RA development within two to six years.

Dr. Dean said, “One, you want to know if someone’s going to get rheumatoid arthritis in their lifetime based on what you can see now. Two, you want to have a sense of when that’s going to happen, both to talk to them,” and as a practical measure for developing clinical trials on prevention that don’t need to follow patients for a long period of time—trials that are essentially unfundable.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

A theme underlying RA prevention trials now is that medium to high ACPA titers, combined with a look at symptoms, can provide an idea of how long a patient has until they develop RA, Dr. Deane said.

Risk scores, more refined treatment geared to prevention and assessing biomarkers and events in follow-up to gauge treatment success all could be in the offing, Dr. Deane said.

Once clinically evident disease appears, a patient will likely have RA “forever,” Dr. Deane said, but earlier treatment still means better outcomes, with fewer irreversible changes to the immune system. Prevention also makes sense from a financial standpoint.

“If I can get to the point where I’m actually keeping people in a prevention state where they’re not that sick, and I can see them and keep them well, I think that’s financially going to be an important model going forward for rheumatologists,” he said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: 2018 ACR/ARHP Annual Meeting, prevention, Remission, treatment de-escalationIssue: January 2019

You Might Also Like:
  • Destructive Arthritis: From Prevention to Progression to Remission
  • Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome
  • California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis
  • EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)